Oxaliplatin (Eloxatin)

==General information==
Class/mechanism: Platinum analog, alkylating-like, which produces interstrand and intrastrand DNA crosslinks that inhibit DNA replication and transcription, causing non-cell cycle specific cytotoxicity and death.Oxaliplatin (Eloxatin) package insertOxaliplatin (Eloxatin) package insert (locally hosted backup)Eloxatin manufacturer's website
Route: IV
Extravasation: irritant (usually), vesicant (rare) 
*Oxaliplatin desensitization protocol
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, or the prescribing information. 
==Diseases for which it is established (work in progress)==
*Colorectal cancer
**Colon cancer
**Rectal cancer
*Hepatocellular carcinoma
==Diseases for which it is used==
*Cholangiocarcinoma
*Chronic lymphocytic leukemia
*Diffuse large B-cell lymphoma
*Esophageal cancer
**Esophageal adenocarcinoma
**Esophageal squamous cell carcinoma
*Extranodal NK- and T-cell lymphoma, nasal type
*Gallbladder cancer
*Gastric cancer
*Mantle cell lymphoma
*Marginal zone lymphoma
*Nasopharyngeal carcinoma
*Pancreatic cancer
*Small bowel adenocarcinoma
*Testicular cancer
*Transformed lymphoma
==Patient drug information==
*Oxaliplatin (Eloxatin) package insert PDF pages 15-16
*Oxaliplatin (Eloxatin) patient drug information (Chemocare)Oxaliplatin (Eloxatin) patient drug information (Chemocare)
*Oxaliplatin (Eloxatin) patient drug information (UpToDate)Oxaliplatin (Eloxatin) patient drug information (UpToDate)
==History of changes in FDA indication==
===Colon cancer===
* 2004-11-04: New indication: used in combination with infusional 5-FU/ LV, is indicated for adjuvant treatment of stage III colon cancer patients who have undergone complete resection of the primary tumor. (Based on MOSAIC)
===Colorectal cancer===
* 2002-08-09: Initial accelerated approval in combination with infusional 5-FU/ LV, is indicated for the treatment of patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed during or within 6 months of completion of first line therapy with the combination of bolus 5-FU/ LV and irinotecan. (Based on BRCC-00036)
**2004-01-09: Converted to regular approval in combination with infusional 5-FU/ LV, is indicated for the treatment of advanced carcinoma of the colon or rectum. (Based on NCCTG N9741)
==History of changes in EMA indication==
*1996-04-12: EURD
==History of changes in PMDA indication==
*2005-03-18: Initial approval for colonic and rectal cancers.
*2009-08-20: New additional indication for post-operative adjuvant chemotherapy for colon cancer.
*2009-09-18: New additional indication for combination therapy with other anticancer drugs (XELOX + BV regimen) for advanced or recurrent colorectal cancer not suited for curative resection.
*2013-12-20: New additional indication and a new dosage for the treatment of unresectable pancreatic cancer.
*2015-03-20: New additional indication and a new dosage for the treatment of unresectable advanced or recurrent gastric cancer.
*2015-11-20: Revised indication for the treatment of gastric cancer.
*2018-09-21: New indication and a new dosage for the treatment of small intestine cancer.
==Also known as==
*Code names: JM-83, RP-54780, SR-96669
*Brand names: Celdach, Coxatin, Curaplat, Cure-X, Dacotin, Dacplat, Eloplat, Eloxatin, Eloxatine, Elplat, Glenoxal, Megaplat, Metaplatin, Neoxal, Oplatin, OxaLitin, Oxasal, Oxaltero, Oxalither, Oxashil, Oxitan, Oxitax, Oxpla, Oxywin, Oxiplat, Oxzucia, Sibatin, X-Plat, Xaloplat, Xylotin, Zildox
==References==
Category:Drugs
Category:Intravenous medications
Category:Platinum agents
Category:Cholangiocarcinoma medications
Category:Chronic lymphocytic leukemia medications
Category:Colon cancer medications
Category:Colorectal cancer medications
Category:Diffuse large B-cell lymphoma medications
Category:Esophageal adenocarcinoma medications
Category:Esophageal cancer medications
Category:Esophageal squamous cell carcinoma medications
Category:Extranodal NK- and T-cell lymphoma, nasal type medications
Category:Gallbladder cancer medications
Category:Gastric cancer medications
Category:Hepatocellular carcinoma medications
Category:Mantle cell lymphoma medications
Category:Marginal zone lymphoma medications
Category:Nasopharyngeal carcinoma medications
Category:Pancreatic cancer medications 
Category:Rectal cancer medications
Category:Small bowel adenocarcinoma medications
Category:Testicular cancer medications
Category:Transformed lymphoma medications
Category:FDA approved in 2002
Category:EMA approved in 1996
Category:PMDA approved in 2005
Category:WHO Essential Cancer Medicine